title: [Intravitreal injections during anticoagulant treatment].
abstract: BACKGROUND
  The number of intravitreal injections has increased steadily over the past few years. The aim of this prospective study was to evaluate the safety of intravitreal injections in patients under concurrent oral anticoagulation or antiplatelet therapy.
  
  
  METHODS
  57 patients who underwent consecutively 80 intravitreal injections of Ranibizumab, Bevacizumab or triamcinolone were included in the study. The majority of the patients was treated with Ranibizumab and received antiplatelet therapy. Post-injection intra- or extraocular haemorrhages were documented.
  
  
  RESULTS
  Small subconjunctival haemorrhages were noted in 45 % of the eyes. No patient experienced a subtotal subconjunctival or vitreous haemorrhage. There was no difference between patients who received oral anticoagulation and those with antiplatelet therapy.
  
  
  CONCLUSIONS
  This study suggests that intravitreal injections can be performed without cessation of oral anticoagulation or antiplatelet therapy.
authors: Augenklinik, Georg-August-Universität Göttingen. wiebke.horn@web.de
authors: W
authors: W
authors: Horn
authors: H
authors: H
authors: Hoerauf
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D000077144:Clopidogrel; D003229:Conjunctival Diseases / Q000139:chemically induced; D006801:Humans; D007267:Injections / Q000009:adverse effects*; D020300:Intracranial Hemorrhages / Q000139:chemically induced; D008268:Macular Degeneration / Q000188:drug therapy*; D010644:Phenprocoumon / Q000008:administration & dosage / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D000069579:Ranibizumab; D012307:Risk Factors; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D014221:Triamcinolone / Q000008:administration & dosage; D014822:Vitreous Body / Q000187:drug effects; D014823:Vitreous Hemorrhage / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014221:Triamcinolone; D000068258:Bevacizumab; D000077144:Clopidogrel; D013988:Ticlopidine; D010644:Phenprocoumon; D001241:Aspirin; D000069579:Ranibizumab